Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anaptysbio (ANAB) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Anaptysbio (ANAB) over the last 10 years, with Q3 2025 value amounting to 45.47%.

  • Anaptysbio's EBIT Margin rose 1212900.0% to 45.47% in Q3 2025 from the same period last year, while for Sep 2025 it was 18.95%, marking a year-over-year increase of 2389000.0%. This contributed to the annual value of 125.93% for FY2024, which is 8323400.0% up from last year.
  • Latest data reveals that Anaptysbio reported EBIT Margin of 45.47% as of Q3 2025, which was up 1212900.0% from 117.55% recorded in Q2 2025.
  • In the past 5 years, Anaptysbio's EBIT Margin ranged from a high of 45.47% in Q3 2025 and a low of 3273.09% during Q1 2022
  • Its 5-year average for EBIT Margin is 995.28%, with a median of 467.91% in 2023.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -31373800bps in 2021, then skyrocketed by 26436700bps in 2024.
  • Anaptysbio's EBIT Margin (Quarter) stood at 3081.8% in 2021, then surged by 83bps to 519.46% in 2022, then increased by 10bps to 467.91% in 2023, then soared by 92bps to 38.68% in 2024, then skyrocketed by 218bps to 45.47% in 2025.
  • Its EBIT Margin stands at 45.47% for Q3 2025, versus 117.55% for Q2 2025 and 99.16% for Q1 2025.